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GLOMERULAR FILTRATION RATE(GFR) is used in the diagno-sis of chronic kidney disease(CKD)1,2 and is an indepen-
dent predictor of all-cause and cardio-
vascular mortality and kidney failure in
a wide range of populations.3-6 Clinical
guidelines recommend reporting esti-
mated GFR when serum creatinine level
is measured1,2; 84% of US laboratories re-
port estimatedGFR.7 Although theModi-
fication of Diet in Renal Disease (MDRD)
Study equation is recommended for es-
timating GFR,1,2,8,9 the Chronic Kidney
Disease Epidemiology Collaboration
(CKD-EPI) has recently proposed an al-
ternative equation, which applies differ-
ent coefficients to the same 4 variables
used in the MDRD Study equation (age,
sex, race, and serum creatinine level).10
The new CKD-EPI equation estimates
measured GFR more accurately than the
MDRD Study equation in most,10-18 butFor editorial comment see p 1976.
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Context The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
more accurately estimates glomerular filtration rate (GFR) than the Modification of Diet
in Renal Disease (MDRD) Study equation using the same variables, especially at higher
GFR, but definitive evidence of its risk implications in diverse settings is lacking.
Objective To evaluate risk implications of estimated GFR using the CKD-EPI equa-
tion compared with the MDRD Study equation in populations with a broad range of
demographic and clinical characteristics.
Design, Setting, and Participants Ameta-analysis of data from 1.1 million adults
(aged 18 years) from 25 general population cohorts, 7 high-risk cohorts (of vascu-
lar disease), and 13 CKD cohorts. Data transfer and analyses were conducted be-
tween March 2011 and March 2012.
MainOutcomeMeasures All-causemortality (84482 deaths from 40 cohorts), car-
diovascularmortality (22176 events from28 cohorts), and end-stage renal disease (ESRD)
(7644 events from 21 cohorts) during 9.4 million person-years of follow-up; the median
ofmean follow-up time across cohortswas 7.4 years (interquartile range, 4.2-10.5 years).
Results EstimatedGFRwas classified into 6 categories (90, 60-89, 45-59, 30-44, 15-
29, and15mL/min/1.73m2) byboth equations. Comparedwith theMDRDStudy equa-
tion, 24.4% and 0.6% of participants from general population cohorts were reclassified
to a higher and lower estimated GFR category, respectively, by the CKD-EPI equation,
and the prevalence of CKD stages 3 to 5 (estimated GFR 60 mL/min/1.73 m2) was
reduced from8.7%to6.3%. In estimatedGFRof 45 to 59mL/min/1.73m2 by theMDRD
Study equation, 34.7% of participants were reclassified to estimated GFR of 60 to 89
mL/min/1.73m2by theCKD-EPI equation andhad lower incidence rates (per 1000person-
years) for the outcomes of interest (9.9 vs 34.5 for all-cause mortality, 2.7 vs 13.0 for
cardiovascular mortality, and 0.5 vs 0.8 for ESRD) compared with those not reclassified.
The corresponding adjusted hazard ratios were 0.80 (95% CI, 0.74-0.86) for all-cause
mortality, 0.73 (95%CI, 0.65-0.82) for cardiovascularmortality, and 0.49 (95%CI, 0.27-
0.88) for ESRD. Similar findings were observed in other estimated GFR categories by the
MDRD Study equation. Net reclassification improvement based on estimated GFR cat-
egories was significantly positive for all outcomes (range, 0.06-0.13; all P .001). Net
reclassification improvementwas similarly positive inmost subgroups defined by age (65
years and65 years), sex, race/ethnicity (white, Asian, and black), and presence or ab-
sence of diabetes and hypertension. The results in the high-risk and CKD cohorts were
largely consistent with the general population cohorts.
Conclusion The CKD-EPI equation classified fewer individuals as having CKD and
more accurately categorized the risk for mortality and ESRD than did theMDRD Study
equation across a broad range of populations.
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not all19,20 studies. However; only 4% of
US laboratories reporting estimated GFR
used the CKD-EPI equation in June
2011; 92% of laboratories still used the
MDRD Study equation and 4% used
other equations.7
A few studies suggest that the better
estimation of GFR by the CKD-EPI
equation is reflected in better clinical
risk prediction than by the MDRD
Study equation.21-24 However, these
studies include predominantly white
populations with higher levels of kid-
ney function. In addition, the implica-
tions of use of the CKD-EPI equation
in the elderly have yet to be eluci-
dated.25,26 The objective of this collab-
orative study was to comprehensively
evaluate whether estimated GFR com-
puted by the CKD-EPI equation pre-
dicts risk for adverse outcomes more
accurately than the MDRD Study equa-
tion in a broad range of populations.
Such information will help clinicians,
laboratories, and policy makers de-
cide whether estimated GFR report-
ing should be based on the MDRD
Study equation or the CKD-EPI equa-
tion.
METHODS
Details of the Chronic Kidney Disease
Prognosis Consortium (CKD-PC) were
described previously.3-6 To be in-
cluded in the consortium, a study had
to have at least 1000 participants (not
applied to studies predominantly en-
rolling patients with CKD6), informa-
tion at baseline on estimated GFR and
urine albumin levels, and a minimum
of 50 events for any of the outcomes of
interest. As recommended,1,2 we pref-
erentially selected ratio of urine albu-
min to creatinine as the measure of al-
buminuria. However, we also accepted
urine albumin excretion and ratio of
urine protein to creatinine as well as a
qualitative measurement using dip-
stick.1 This analysis consists of data
from 45 cohorts (25 general popula-
tion cohorts, 7 high-risk cohorts with
participants selected for cardiovascu-
lar or kidney disease risk factors, and
13 CKD cohorts). Data transfer (from
collaborating cohorts to the CKD-PC
Data Coordinating Center) and analy-
ses for the present study were con-
ducted between March 2011 and March
2012. This study is based on second-
ary data analysis of a preexisting, de-
identified, and unlinked data set, and
was approved by the institutional re-
view board at the Johns Hopkins
Bloomberg School of Public Health. In-
formation about ethical review of in-
dividual studies is available in the
publications of the constituent co-
horts.21,24,27-69
We calculated estimated GFR from
serum creatinine standardized to iso-
tope dilution mass spectrometry using
the MDRD Study equation9 and the
CKD-EPI equation.10 For studies in
which creatinine measurement was not
standardized to isotope dilution mass
spectrometry, we reduced the creati-
nine levels by 5%, which is the calibra-
tion factor used to adjust nonstandard-
ized MDRD samples to this type of
spectrometry.70
Diabetes mellitus was defined as fast-
ing glucose level of 7.0 mmol/L or
greater, nonfasting glucose level of 11.1
mmol/L or greater, hemoglobin A1c of
6.5% or greater, use of glucose-
lowering drugs, or self-reported diabe-
tes (to convert glucose to mg/dL, di-
vide by 0.0555; hemoglobin A1c to a
proportion, multiply by 0.01). Hyper-
tension was defined as systolic blood
pressure of 140 mm Hg or greater, dia-
stolic blood pressure of 90 mm Hg or
greater, or use of any antihypertensive
medication. Hypercholesterolemia was
defined as total cholesterol level of 6.0
mmol/L or greater (5.0 mmol/L in
people with prior cardiovascular dis-
ease) or use of lipid-lowering drugs (to
convert cholesterol to mg/dL, divide by
0.0259). Cardiovascular disease his-
tory was defined as a history of myo-
cardial infarction, coronary revascular-
ization, heart failure, or stroke. Smoking
was dichotomized as current vs for-
mer smokers or nonsmokers. Race/
ethnicity was categorized as white,
Asian, black, Hispanic, and other.
The outcomes of interest were all-
cause mortality, cardiovascular mortal-
ity, and end-stage renal disease (ESRD).
Cardiovascular mortality was defined as
death due to myocardial infarction, heart
failure, sudden cardiac death, or stroke.
End-stage renal disease was defined as
the start of renal replacement therapy or
death due to kidney disease other than
acute kidney injury.
Statistics were first obtained within
each study and then a meta-analysis was
performed across studies using a ran-
dom-effects model. Analyses were re-
stricted to individuals aged 18 years or
older. Any individual with missing val-
ues for estimated GFR or albuminuria
at baseline was excluded. Missing val-
ues for all other covariates were esti-
mated by mean imputation. The analy-
sis overview and analytic notes for
individual studies are described in the
eAppendix 1 at http://www.jama
.com). Heterogeneity was quantified
using the 2 test and the I2 statistic. We
conducted a meta-regression analysis
with a random-effects model to ex-
plore sources of heterogeneity. A meta-
analysis was performed separately on
the general population, high-risk, and
CKD cohorts.
We evaluated the distribution and
risk relationship for estimated GFR
separately for both equations. Cox
proportional hazards models were fit-
ted with estimated GFR linear splines
(knots at 30, 45, 60, 75, 90, and 105
mL/min/1.73 m2 [the 105 mL/min/
1.73 m2 knot was not applied to CKD
cohorts]). All Cox models were
adjusted for age, sex, race/ethnicity
(blacks vs nonblacks), smoking (cur-
rent vs former or nonsmokers), his-
tory of cardiovascular disease, systolic
blood pressure (continuous), diabetes,
serum total cholesterol concentration
(continuous), body mass index (con-
tinuous), and albuminuria (log-
transformed ratio of urine albumin to
creatinine, log-transformed ratio of
urine protein to creatinine as continu-
ous variables, or dipstick as a categori-
cal variable [negative, trace, 1 , 2 ,
and 3 ]). From these models, hazard
ratio (HR) was computed for each 1
mL/min/1.73 m2 of estimated GFR
from 15 to 120 mL/min/1.73 m2 with a
reference point at 95 mL/min/1.73 m2
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(50 mL/min/1.73 m2 for CKD cohorts).
Modeldiscriminationwasassessedusing
the c statistic, which allows for censor-
ing.71
We cross-tabulated estimated GFR
using clinically relevant categories
(90, 60-89, 45-59, 30-44, 15-29,15
mL/min/1.73m2)1,2 and evaluated the
proportion of participants in each cat-
egory of estimated GFR by the MDRD
Study equation that was reclassified by
the CKD-EPI equation. To evaluate fac-
tors associated with reclassification,
baseline characteristics of participants
in each study were compared accord-
ing to the reclassification status by the
CKD-EPI equation (reclassified up-
ward to a higher estimated GFR cat-
egory, not reclassified, or reclassified
downward to a lower estimated GFR
category). Because there were few par-
ticipants with an estimated GFR of less
than 15 mL/min/1.73 m2 in the gen-
eral population cohorts (0.1%) and
in high-risk cohorts (0.2%), we only re-
ported results for this estimated GFR
category in the CKD cohorts.
Given that GFR category is a cen-
tral measure for defining, staging, and
managing CKD (including indica-
tions for referral),1,2 we designated a
priori the effect of reclassification in es-
timated GFR categories as the primary
analysis.21-23 We assessed risk of clini-
cal outcomes among participants who
were reclassified for estimated GFR
compared with those who were not re-
classified. Overall improvement in re-
classification based on estimated GFR
was assessed by applying net reclassi-
fication improvement (NRI).21,72 To as-
sess generalizability, we calculated NRI
in subgroups according to age (65
years and 65 years), sex, race/
ethnicity (white, Asian, and black), and
presence or absence of diabetes and hy-
pertension. Due to sparse data, we could
not reliably investigate Hispanics and
other racial/ethnic groups. The NRI also
was estimated in subgroups according
to albuminuria levels. All analyses were
conducted using Stata version 11.2
(StataCorp). A P value of less than .05
was considered statistically signifi-
cant.
RESULTS
Participants from 45 cohorts were from
40 countries or regions of Asia, Eu-
rope, North America and South
America, the Middle East, and Ocea-
nia. Baseline characteristics of each co-
hort are shown in eTable 1 at http:
//www.jama.com. Overall, 1.1 million
adults (940 366 from general popula-
tion, 151 494 from high-risk, and
38 612 from CKD cohorts) were fol-
lowed up for 9.4 million person-years
(the median of mean follow-up time
across collaborating cohorts was 7.4
years [interquartile range, 4.2-10.5
years]). Forty cohorts reported on
84 482 deaths (61 770 from general
population, 13 693 from high-risk, and
9019 from CKD cohorts); 28 cohorts
reported on 22 176 cardiovascular dis-
ease deaths (17 009 from general popu-
lation, 4271 from high-risk, and 896
from CKD cohorts); and 21 cohorts re-
ported on 7644 ESRD events (730 from
general population, 954 from high-
risk, and 5960 from CKD cohorts).
Mean estimated GFR was higher
when computed by the CKD-EPI equa-
tion than by the MDRD Study equa-
tion in the general population cohorts
(88.9 vs 81.5 mL/min/1.73 m2, respec-
tively; FIGURE 1A) and in the high-
risk cohorts (84.6 vs 80.6 mL/
min/1.73 m2; eFigure 1A) but was com-
parable in the CKD cohorts (41.4 vs
40.6 mL/min/1.73 m2) (eFigure 2A).
The shift of distribution toward higher
estimated GFR by the CKD-EPI equa-
tion was more evident in younger
people (65 years), females, and non-
blacks (eFigures 3-5). Accordingly, the
prevalence of CKD stages 3 to 5 (60
mL/min/1.73 m2) was lower by the
CKD-EPI equation than by the MDRD
Study equation in the general popula-
tion cohorts (6.3% vs 8.7%, respec-
tively) and in the high-risk cohorts
(14.6% vs 17.7%). The lower preva-
lence of CKD stages 3 to 5 by the CKD-
EPI equation was observed in most of
the individual cohorts; there was a small
increase in only 2 cohorts of elderly par-
ticipants30,39(eFigure 6).
The pattern of the estimated GFR risk
relationship was similar for both equa-
tions in the general population co-
horts after adjusting for potential con-
founders (Figure 1B-D). However, the
adjusted HR of lower estimated GFR
compared with estimated GFR of 95
mL/min/1.73 m2 became significant at
a higher level by the CKD-EPI equa-
tion than by the MDRD Study equa-
tion, particularly for cardiovascular
mortality (77 vs 68 mL/min/1.73 m2, re-
spectively) and ESRD (82 vs 70 mL/
min/1.73 m2). Within the range of es-
timated GFR of less than 45 mL/
min/1.73 m2, the HRs were largely com-
parable between both equations for the
mortality outcomes. The steeper risk
gradient along with low estimated GFR
was more evident in the unadjusted
analysis for mortality (eFigure 7). The
higher risk of all-cause and cardiovas-
cular mortality in the higher esti-
mated GFR range (105-120 mL/min/
1.73 m2) was more pronounced for the
CKD-EPI equation than the MDRD
Study equation. This effect was not ob-
served in the unadjusted analysis. Simi-
lar estimated GFR risk relationships
were observed in the high-risk and CKD
cohorts (eFigure 1B-D and eFigure
2B-D), but the higher risk at higher lev-
els of estimated GFR was not evident.
Using these models with estimated GFR
splines, traditional risk factors, and al-
buminuria, the c statistic, which fo-
cuses on ranking alone and ignores ab-
solute levels and categories,73 produced
results that were almost identical for the
CKD-EPI and MDRD Study equations
in the general population cohorts for
all-cause mortality (0.783 [95% CI,
0.758-0.807] vs 0.783 [95% CI, 0.759-
0.808], respectively), for cardio-
vascular mortality (0.835 [95% CI,
0.800-0.869] vs 0.835 [95% CI, 0.801-
0.869]) and for ESRD (0.920 [95% CI,
0.888-0.953] vs 0.919 [95% CI, 0.885-
0.952]). Similar findings were ob-
served in the high-risk and CKD co-
horts (eTable 2).
In the general population cohorts,
25.0% of participants were reclassi-
fied by the CKD-EPI equation (24.4%
to a higher estimated GFR category and
0.6% to a lower estimated GFR cat-
egory) (FIGURE 2). Most reclassifica-
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tion occurred among participants with
estimated GFR between 45 and 89 mL/
min/1.73 m2 by the MDRD Study equa-
tion. A similar reclassification pattern
was observed in the high-risk cohorts,
although there was less reclassifica-
tion (15.4% upward and 1.2% down-
ward; eFigure 8). In the CKD cohorts,
we observed much less upward reclas-
Figure 2. Reclassification Across Estimated GFR Categories by the CKD-EPI Equation From Estimated GFR Categories Based on the MDRD
Study Equation
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Cardiovascular Mortality, and End-Stage Renal Disease
Distribution of estimated GFRA
0.03
0.02
0.01
0
0 30 60 90 120 150 180
Estimated GFR, mL/min/1.73 m2
P
ar
tic
ip
an
ts
, P
ro
po
rt
io
n
All-cause mortalityB
4.0
3.0
2.0
1.5
1.0
0.8
15 30 45 60 75 10590 120
Estimated GFR, mL/min/1.73 m2
A
dj
us
te
d 
H
R
Cardiovascular mortalityC
4.0
3.0
2.0
1.5
1.0
0.9
15 30 45 60 75 10590 120
Estimated GFR, mL/min/1.73 m2
A
dj
us
te
d 
H
R
End-stage renal diseaseD
1500
30
10
100
500
0.3
3
1
0.1
15 30 45 60 75 10590 120
Estimated GFR, mL/min/1.73 m2
A
dj
us
te
d 
H
R
MDRD Study
Equation for estimated GFR
CKD-EPI
MDRD Study
Equation for estimated GFR
CKD-EPI
Reference value
MDRD Study
Equation for estimated GFR
CKD-EPI
Reference value
MDRD Study
Equation for estimated GFR
CKD-EPI
Reference value
A, Distribution based on kernel density estimation (proportion is for each integer estimated glomerular filtration rate [GFR]). Dotted vertical lines define GFR categories
used for chronic kidney disease staging.1,2 B-D, Error bars indicate 95% confidence intervals for estimated GFR by the CKD-EPI equation. Tinted bands indicate 95%
confidence intervals for estimated GFR by the MDRD Study equation. Reference (open circle) is estimated GFR of 95 mL/min/1.73 m2. The filled circles (black and blue
dots) represent statistical significance (P.05). Adjustments were made for age, sex, race/ethnicity, smoking, history of cardiovascular disease, systolic blood pressure,
diabetes, serum total cholesterol concentration, body mass index, and albuminuria. CKD-EPI indicates Chronic Kidney Disease Epidemiology Collaboration; MDRD,
Modification of Diet in Renal Disease.
RISK PREDICTION USING CKD-EPI VS MDRD FOR ESTIMATED GLOMERULAR FILTRATION RATE
1944 JAMA, May 9, 2012—Vol 307, No. 18 ©2012 American Medical Association. All rights reserved.
Downloaded From: http://jama.jamanetwork.com/ by a MEDICAL LIBRARY YONSEI UNIVERSITY User  on 08/05/2013
sification (6.6%) but slightly more
downward reclassification (3.2%) by the
CKD-EPI equation (eFigure 9).
Participants who were reclassified
upward to a higher estimated GFR cat-
egory by the CKD-EPI equation were
more likely to be younger, female, and
nonblack, and thus have fewer comor-
bid conditions such as hypertension,
diabetes, and clinically significant al-
buminuria compared with individuals
who remained in the same estimated
GFR category (TABLE 1, TABLE 2, and
eTable 3). In contrast, the participants
reclassified downward to a lower esti-
mated GFR category by the CKD-EPI
equation were much older than those
who were not reclassified in most stud-
ies (mean age in general population co-
horts, 77 years vs 49 years, respec-
tively). Blacks tended to be reclassified
less frequently (in either direction) in
the general population cohorts but were
reclassified downward more fre-
quently at a lower GFR range (CKD co-
horts) compared with nonblacks.
Participants in general population co-
horts who were reclassified upward and
downward by the CKD-EPI equation
had consistently lower and higher inci-
dence rates for all outcomes, respec-
tively, than those who remained in the
same estimated GFR category (TABLE3).
This association remained the same even
after adjustment for potential confound-
ers, with only a few exceptions (none of
which were significant). When we fo-
cused on clinically important upward re-
classification from CKD stage 3a (esti-
mated GFR 45 to 59 mL/min/1.73 m2)
to mildly reduced estimated GFR (60
to 89 mL/min/1.73 m2), this reclas-
sification was associated with lower
incidence rates compared with no re-
classification (incidence rate per 1000
person-years, 9.9 vs 34.5 [difference,
−24.6] for all-cause mortality, 2.7 vs 13.0
[−10.3] for cardiovascular mortality, and
0.5 vs 0.8 [−0.3] for ESRD). Of note, this
reclassification was associated with a
20% to 51% lower risk of these out-
comes even after the adjustment for tra-
ditional risk factors and albuminuria. We
obtained similar results for the groups
either younger or older than 65 years of
age (eTable 4 and eTable 5). Among the
statistically significant reclassifications
Table 1. Characteristics of Participants in General Population Cohorts According to Reclassification Status by CKD-EPI Equation Compared
With MDRD Study Equation for Estimated GFR
General Population
Cohortsa
Total
No.
Moved Upward to Higher
GFR Category No Reclassification
Moved Downward to Lower
GFR Category
Overall, %
Mean
Age, y
Females;
Blacks;
Albuminuria, %b Overall, %
Mean
Age, y
Females;
Blacks;
Albuminuria, %b Overall, %
Mean
Age, y
Females;
Blacks;
Albuminuria, %b
Aichi27 4731 19 48 20; 0; 3 81 48 20; 0; 2 0 NA NA; NA; NA
ARIC21,c 11 441 8 59 58; 15; 7 90 63 56; 23; 8 2 71 21; 6; 12
AusDiab24,c 11 179 25 45 60; 0; 4 74 54 54; 0; 7 1 77 27; 0; 23
Beaver Dam CKD28 4857 16 54 64; 0; 2 81 63 55; 0.03; 5 2 77 40; 0; 5
Beijing29,c 1559 17 54 65; 0; 8 83 61 48; 0; 5 1 74 20; 0; 23
CHS30,c 2988 0.3 73 89; 0; 33 88 78 60; 17; 21 11 81 46; 14; 20
CIRCS31 11 871 21 52 69; 0; 3 79 54 59; 0; 3 0 NA NA; NA; NA
COBRA32,c 2872 9 52 49; 0; 12 89 51 53; 0; 9 2 81 40; 0; 15
ESTHER33 9641 14 59 67; 0; 9 85 62 53; 0; 12 1 72 33; 0; 12
Framingham34,c 2956 17 55 58; 0; 9 82 59 52; 0; 13 1 75 25; 0; 21
Gubbio35,c 1681 23 53 52; 0; 3 77 55 56; 0; 4 0 NA NA; NA; NA
HUNT36,c 9659 12 53 64; 0; 6 84 63 54; 0; 13 4 77 45; 0; 19
IPHS37 95 451 18 53 77; 0; 2 81 60 64; 0; 3 0.3 76 12; 0; 4
MESA38,c 6733 12 56 61; 13; 7 86 63 52; 29; 10 2 78 32; 44; 25
MRC39 12 371 1 77 100; 0; 5 91 81 62; 0; 8 8 84 42; 0; 8
NHANES III40,c 15 563 13 44 55; 16; 8 86 46 53; 29; 12 2 81 35; 19; 27
Ohasama41 1956 14 58 80; 0; 7 85 64 62; 0; 8 1 83 22; 0; 39
Okinawa 198342 9599 22 43 61; 0; 17 78 54 59; 0; 22 0.4 83 52; 0; 32
Okinawa 199343 93 216 21 46 60; 0; 3 79 57 57; 0; 4 1 81 36; 0; 6
PREVEND44,c 8385 27 44 58; 0.4; 8 73 51 47; 1; 12 0.2 72 15; 0; 30
RanchoBernardo45,c 1474 10 58 66; 0; 8 83 71 59; 0.1; 15 7 84 56; 0; 18
REGARDS46,c 27 306 11 59 68; 18; 8 85 65 53; 43; 16 4 77 36; 30; 21
Severance47 76 201 29 42 53; 0; 5 71 47 48; 0; 5 0.1 77 20; 0; 16
Taiwan48 515 573 29 37 52; 0; 1 71 43 50; 0; 2 0.1 80 22; 0; 9
ULSAM49,c 1103 1 71 0; 0; 11 93 71 0; 0; 16 6 71 0; 0; 19
Total 940 366 24 43 57; 1; 3 75 49 52; 2; 4 1 77 24; 2; 10
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; NA, data not applicable.
aThe study acronyms and abbreviations are listed in eAppendix 2 at http://www.jama.com.
bFor albuminuria, this is the proportion of participants with ratio of urine albumin to creatinine of 30 mg/g or greater, ratio of protein to creatinine of 50 mg/g or greater, or dipstick
protein level of 1 or greater.
cThis study included ratio of urine albumin to creatinine.
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in Table 3, heterogeneity across stud-
ies was minimal to moderate (I2=0% to
52.5%; P values ranged from 0.82 to
0.006). Similar findings were observed
in the high-risk (eTable 6) and CKD co-
horts (eTable 7). For ESRD, analysis
with mortality as a competing risk pro-
vided similar findings (eTable 8).
In the general population cohorts,
NRI was significantly positive (favor-
ing the CKD-EPI equation) for all out-
comes (0.11 [95% CI, 0.09-0.13] for
all-cause mortality, 0.13 [95% CI, 0.09-
0.16] for cardiovascular mortality, and
0.06 [95% CI, 0.02-0.10] for ESRD)
(FIGURE 3). There was high heteroge-
neity between individual cohorts for
overall NRI (I2=71%-97%; all P .01).
However, this heterogeneity reflected
quantitative rather than qualitative dif-
ferences because the CKD-EPI equa-
tion was favored in almost all general
population cohorts (eFigures 10-12).
We conducted a meta-regression analy-
sis with the covariates (eTable 9). Stud-
ies with higher mean age and preva-
lence of diabetes tended to have lower
NRI for cardiovascular mortality (eFig-
ure 13 and eFigure 14). The NRI for
other associations did not vary signifi-
cantly across studies.
The NRI was positive in most of the
subgroups according to age, sex, race/
ethnicity, and presence or absence of
diabetes and hypertension (Figure 3).
The NRI was comparable between fe-
males and males and between those
younger than 65 years and those aged
65 years or older except for a lower NRI
in those aged 65 years or older for
ESRD. The NRI was positive even in the
age category of 75 years or older for all-
cause mortality (0.03 [95% CI, 0.02 to
0.05]) and cardiovascular mortality
(0.02 [95% CI, 0.01 to 0.03]). The NRI
was negative but not significant for
ESRD (−0.04 [95% CI, −0.10 to 0.02],
P= .15). The NRI for mortality out-
comes was lower in blacks compared
with whites and Asians but still signifi-
cantly favored the CKD-EPI equation.
With further stratification by the com-
bination of these demographic vari-
ables, the NRI was positive (favoring the
Table 2. Characteristics of Participants in High-Risk and Chronic Kidney Disease (CKD) Cohorts According to Reclassification Status by
CKD-EPI Equation Compared With MDRD Study Equation for Estimated GFR
Cohorta
Total
No.
Moved Upward to Higher
GFR Category No Reclassification
Moved Downward to Lower
GFR Category
Overall, %
Mean
Age, y
Females;
Blacks;
Albuminuria, %b Overall, %
Mean
Age, y
Females;
Blacks;
Albuminuria, %b Overall, %
Mean
Age, y
Females;
Blacks;
Albuminuria, %b
High-risk
ADVANCE50,c 10 595 10 62 57; 0.4; 31 88 66 41; 0.3; 31 2 74 25; 1; 26
CARE51 4098 17 54 17; 2; 12 83 60 13; 4; 14 0.2 73 0; 0; 57
KEEP52 77 902 15 48 72; 21; 10 84 55 68; 33; 13 1 79 51; 36; 21
KP Hawaii53,d 39 884 15 51 54; 0; 29 84 60 50; 0; 34 2 82 38; 0; 45
MRFIT54 12 854 28 44 0; 3; 4 72 47 0; 9; 4 0 NA NA; NA; NA
Pima55,c 5066 4 46 68; 0; 37 96 32 56; 0; 19 0.2 76 50; 0;t50
ZODIAC56,c 1095 10 58 56; 0; 25 88 69 58; 0; 41 2 79 27; 0; 46
Subtotal 151 494 15 49 59; 11; 17 83 56 53; 18; 19 1 72 40; 18; 28
CKD
AASK57,d 1094 6 46 66; 100; 63 92 55 37; 100; 62 2 66 21; 100; 54
BC CKD58,c 17 426 6 52 56; 0.1; 76 90 70 45; 0.4; 75 4 82 34; 1; 74
CRIB59,c 308 3 49 38; 0; 63 95 62 34; 6; 87 2 77 17; 17; 100
Geisinger60
ACRc 3361 3 59 63; 3; 50 96 71 54; 2; 43 1 79 6; 0; 56
Dipstick 4509 3 57 80; 6; 32 96 72 62; 1; 25 2 81 27; 3; 27
GLOMMS-161
ACRc 537 2 54 33; 0; 67 93 73 52; 0; 51 4 80 42; 0; 38
PCRd 470 4 41 47; 0; 88 91 70 48; 0; 95 5 83 43; 0; 100
KPNW62 1627 10 62 72; 1; 25 86 72 54; 3; 32 4 82 53; 3; 31
MASTERPLAN63,c 636 11 49 47; 3; 78 88 62 29; 3; 86 1 72 50 0; 75
MDRD64,d 1730 14 45 50; 5; 80 86 52 38; 13; 83 1 67 29; 64; 86
MMKD65,d 202 17 39 41; 0; 94 83 48 33; 0; 95 0 NA NA; NA; NA
NephroTest66,c 928 9 48 33; 8; 51 89 61 31; 10; 65 2 75 0; 13; 73
RENAAL67,c 1513 9 55 34; 8; 100 90 61 37; 15; 100 1 68 0; 67; 100
STENO68,c 886 26 42 48; 0; 46 74 44 42; 0; 50 0.1 74 0; 0; 0
Sunnybrook69,c 3385 6 52 52; 0; 83 89 71 44; 0; 84 5 82 26; 0; 86
Subtotal 38 612 7 53 58; 5; 67 90 68 47; 5; 66 3 79 28; 10; 65
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; NA, data not applicable.
aThe study acronyms and abbreviations are listed in eAppendix 2 at http://www.jama.com.
bFor albuminuria, this is the proportion of participants with ratio of urine albumin to creatinine (ACR) of 30 mg/g or greater, ratio of protein to creatinine (PCR) of 50 mg/g or greater,
or dipstick protein level of 1 or greater.
cThis study included ACR.
dThis study included PCR.
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CKD-EPI equation) in 33 of 36 com-
parisons and was statistically signifi-
cant in 17 comparisons (eTable 10).
None of 3 negative NRIs (favoring the
MDRD Study equation) were signifi-
cant. Similarly, the NRI was positive in
most subgroups in the high-risk and
CKD cohorts (eFigure 15, eFigure 16,
eTable 11, and eTable 12). The NRI also
was positive in most subgroups de-
fined according to albuminuria level
(eTable 13).
Table 3. Clinical Outcomes for the General Population Cohorts According to Reclassification Status by CKD-EPI Equation Compared With
MDRD Study Equation for Estimated GFR
MDRD
Estimated
GFR
Category,
mL/min/
1.73 m2
All-Cause Mortality
(n = 61 426 Events)
by CKD-EPI GFR Reclassification
Cardiovascular Mortality
(n = 16 923 Events)
by CKD-EPI GFR Reclassification
End-Stage Renal Disease
(n = 666 Events)
by CKD-EPI GFR Reclassification
Upward
(n = 5586
Events)
None
(n = 53 601
Events)
Downward
(n = 2239
Events)
Upward
(n = 1113
Events)
None
(n = 14 979
Events)
Downward
(n = 831
Events)
Upward
(n = 60
Events)
None
(n = 588
Events)
Downward
(n = 18
Events)
90
CIRa NAb 3.8 52.9 NAb 0.8 22.3 NAb 0.3 0.4
AHRc NAb 1
[Reference]
1.02
(0.89-1.18)
NAb 1
[Reference]
1.24
(1.01-1.53)
NAb 1
[Reference]
1.54
(0.50-4.78)
60-89
CIRa 2.2 10.2 95.1 0.4 3.0 46.0 0.1 0.2 2.3
AHRc 1.03
(0.98-1.08)
1
[Reference]
0.98
(0.85-1.14)
0.93
(0.85-1.02)
1
[Reference]
1.21
(1.01-1.43)
0.47
(0.24-0.93)
1
[Reference]
4.44
(1.52-13.00)
45-59
CIRa 9.9 34.5 111.6 2.7 13.0 52.3 0.5 0.8 1.6
AHRc 0.80
(0.74-0.86)
1
[Reference]
1.15
(1.03-1.27)
0.73
(0.65-0.82)
1
[Reference]
1.25
(1.07-1.48)
0.49
(0.27-0.88)
1
[Reference]
2.67
(0.73-9.72)
30-44
CIRa 18.2 66.4 134.5 6.0 27.3 56.4 4.6 7.0 13.7
AHRc 0.74
(0.61-0.88)
1
[Reference]
1.11
(0.79-1.55)
0.75
(0.54-1.05)
1
[Reference]
1.25
(0.68-2.31)
0.95
(0.43-2.07)
1
[Reference]
1.35
(0.51-3.56)
15-29
CIRa 33.4 88.1 NAd 15.7 33.6 NAd 59.5 59.7 NAd
AHRc 1.04
(0.51-2.15)
1
[Reference]
NAd 1.66
(0.44-6.30)
1
[Reference]
NAd 1.13
(0.36-3.54)
1
[Reference]
NAd
Abbreviations: AHR, adjusted hazard ratio; CIR, crude incidence rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; GFR, glomerular filtration rate; MDRD, Modi-
fication of Diet in Renal Disease.
aPer 1000 person-years.
bNA indicates inapplicable.
cAdjusted for age, sex, race/ethnicity, smoking, systolic blood pressure, total cholesterol, diabetes, history of cardiovascular disease, body mass index, and albuminuria.
dNA indicates unreliable due to the small number of participants.
Figure 3.Meta-analyses of Net Reclassification Improvements (NRIs) for All-Cause Mortality, Cardiovascular Mortality, and End-Stage Renal
Disease
Overall
Sex
Female
Male
Diabetes
No
Yes
Hypertension
No
Yes
Age, y
<65
≥65
Race/ethnicity
White
Black
Asian
Favors
MDRD
Favors
CKD-EPI
No. of 
Cohorts
23
23
23
23
23
22
23
15
5
10
20
21
–0.1 0 0.1 0.2
NRI (95% CI)
All-cause mortality
Favors
MDRD
Favors
CKD-EPI
No. of 
Cohorts
18
18
17
18
18
17
18
13
4
5
15
18
–0.1 0 0.1 0.2
NRI (95% CI)
Cardiovascular mortality
Favors
MDRD
Favors
CKD-EPI
No. of 
Cohorts
5
5
3
2
3
5
5
3
2
2
5
5
–0.1 0 0.1 0.2
NRI (95% CI)
End-stage renal disease
The sizes of the data markers are proportional to the inverse of the variance of the NRIs.
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COMMENT
In our data from more than 1 million
participants residing in 40 countries or
regions, approximately one-fourth of
participants were reclassified to a higher
estimated GFR category by the CKD-
EPI equation compared with the MDRD
Study equation (24.4% in the general
population cohorts, 15.4% in the high-
risk cohorts, and 6.6% in the CKD co-
horts), lowering the prevalence of CKD
in all cohorts except for the elderly. Par-
ticipants who were reclassified up-
ward had lower risks of mortality and
ESRD compared with those not reclas-
sified even after adjusting for age, sex,
race/ethnicity, and other potential con-
founders. Individuals who were reclas-
sified downward (0.7%) had higher risk
than those who were not reclassified.
Positive NRIs also support better over-
all reclassification by the CKD-EPI
equation. Although we observed quan-
titative heterogeneity in some analy-
ses, most of the studies were in agree-
ment with the pooled results (eFigures
10-12). Importantly, a better risk cat-
egorization by the CKD-EPI equation
compared with the MDRD Study equa-
tion was consistent in almost all sub-
groups defined by age, sex, race/
ethnicity, and clinical characteristics.
Our results confirm and extend re-
sults from previous literature.21-24 First,
we observed that the CKD-EPI equa-
tion is a better predictor of risk than the
MDRD Study equation in CKD co-
horts as well as in cohorts with higher
estimated GFR. Improved or similar
performance across the range of esti-
mated GFR is important for clinical
implementation. Second, although the
elderly were less often reclassified by
the CKD-EPI equation compared with
younger people, their future risk also
was more correctly classified. Third, we
found that the CKD-EPI equation pre-
dicts clinical risk more accurately than
the MDRD Study equation in Asians. Al-
though there is debate about which es-
timated GFR equation to use in Asia,74,75
our results suggest that the CKD-EPI
equation would be a better option for
risk prediction than the MDRD Study
equation. Fourth, we showed that the
CKD-EPI equation categorizes risk
slightly more accurately than or at least
as well as the MDRD Study equation in
blacks, even though reclassification is
less common in blacks than in whites
and Asians. Fifth, we showed that the
CKD-EPI equation provides more ac-
curate risk categorization than the
MDRD Study equation even after con-
sidering albuminuria, a measure of kid-
ney damage. Recent reports suggest
using albuminuria in addition to GFR
for CKD staging and risk classifica-
tion.76,77 Our findings suggest the CKD-
EPI equation will be more useful than
the MDRD Study equation for this ap-
plication. Finally, we showed im-
proved risk prediction for ESRD, in ad-
dition to mortality and cardiovascular
disease shown in most of the previous
studies.21-24
The CKD-EPI and MDRD Study
equations estimate the same physiologi-
cal function (GFR) using identical vari-
ables, thus the comparison of out-
come prediction by 2 equations differs
from the more common comparison of
2 models with and without a new bio-
marker. Because the same variables ap-
pear in both equations in our study, the
difference in predicted risk between the
2 equations should not be expected to
be as large as would be sought when
adding a new biomarker. Conse-
quently, we did not anticipate improve-
ments in less sensitive statistics (such
as the c statistic), which ignore abso-
lute levels and categories and focus on
ranking alone.73 This is particularly the
case when age, sex, and race/ethnicity
are included in the prediction model be-
cause coefficients for these variables can
compensate for worse prediction by es-
timated GFR by the MDRD Study equa-
tion compared with the CKD-EPI equa-
tion.21
From another perspective, the use of
the identical variables in the CKD-EPI
equation requires no additional labo-
ratory costs and enables relatively easy
implementation with computerized al-
gorithms. Therefore, a significant over-
all improvement in risk categoriza-
tion by the CKD-EPI equation, even if
small, would support its clinical use in
place of the MDRD Study equation. At
this time, only a small proportion of
clinical laboratories in the United States
have switched to the CKD-EPI equa-
tion for estimated GFR reporting.7 In
this context, clinically important re-
classification crossing the threshold for
CKD definition from CKD stage 3a to
mildly reduced estimated GFR (60 to
89 mL/min/1.73m2) was observed in
our study in one-third of individuals
with estimated GFR by the MDRD
Study equation between 45 and 59 mL/
min/1.73m2. In the general popula-
tion cohorts, these individuals had
lower risk of mortality and ESRD com-
pared with those who were not reclas-
sified (crude incidence rate difference
of −24.6 to −0.3 per 1000 person-
years and 20% to 51% lower adjusted
HR). Given both lower CKD preva-
lence estimates and better risk catego-
rization, the use of the CKD-EPI equa-
tion would contribute to a more
appropriate allocation of health care re-
sources and more targeted prevention
and management of CKD complica-
tions.
The paradoxically increased mortal-
ity risk at higher estimated GFR is noted
in several studies and may be due to
confounding by muscle wasting sec-
ondary to ill health.21 With the CKD-
EPI equation, this risk was not evi-
dent in the unadjusted analysis but was
evident after age adjustment, suggest-
ing the CKD-EPI equation does not
fully overcome this limitation inher-
ent to creatinine-based estimated GFR
equations. Other filtration markers not
related to muscle mass such as serum
cystatin C78,79 might help to resolve this
issue.
Some limitations to our study should
be mentioned. Measurements of cre-
atinine were not standardized in all
studies; however, we observed similar
results when we limited our analysis to
studies with serum creatinine measure-
ments standardized to isotope dilu-
tion mass spectrometry (data not
shown). Most of the participants re-
corded as blacks were from studies in
the United States. Although there are
various ethnic groups within Asia (eg,
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South Asian and Eastern Asian), we
analyzed these groups together. Fur-
ther analyses will be required for racial/
ethnic groups not tested in this study.
Overall, the CKD-EPI creatinine-
based equation more accurately classi-
fied individuals with respect to risk of
mortality and ESRD compared with the
MDRD Study equation. Given more ac-
curate GFR estimation,10 lower CKD
prevalence estimates, and better risk
categorization by the CKD-EPI equa-
tion without additional laboratory costs,
its implementation for estimated GFR
reporting could contribute to more ef-
ficient and targeted prevention and
management of CKD-related out-
comes.
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